Loading clinical trials...
Loading clinical trials...
Safety and Efficacy of Escalating Doses of Two LEO 43204 Formulations Applied Once Daily for Two Consecutive Days on Full Face or Approximately 250 cm2 (40 in2) on the Chest in Subjects With Actinic Keratosis
Conditions
Interventions
LEO 43204 Formulation 1
LEO 43204 Formulation 2
+6 more
Locations
25
United States
Omni Dermatology
Phoenix, Arizona, United States
Torrance Clinical Research Institute Inc.
Lomita, California, United States
Dermatology Cosmetic Laser Medical Associates of La Jolla, Inc.
San Diego, California, United States
Leavitt Medical Associates of Florida
Ormond Beach, Florida, United States
Clinical Research Center, Morsani Center for Advanced Healthcare
Tampa, Florida, United States
Research Institute of Deaconess Clinic
Evansville, Indiana, United States
Start Date
October 1, 2013
Primary Completion Date
November 1, 2014
Completion Date
November 1, 2014
Last Updated
March 6, 2025
NCT07340697
NCT06778434
NCT07137819
NCT06648447
NCT05688904
NCT07286318
Lead Sponsor
LEO Pharma
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions